16 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of the 4-aminopiperidine-based compound EM127 for the site-specific covalent inhibition of SMYD3.
Institute of Organic Synthesis and Photoreactivity - National Research Council
Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase.
University of California San Francisco
Discovery of tetrahydrofuranyl spirooxindole-based SMYD3 inhibitors against gastric cancer via inducing lethal autophagy.
Chengdu University of Traditional Chinese Medicine
Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets.
University of Palermo
Fascinating Transformation of SAM-Competitive Protein Methyltransferase Inhibitors from Nucleoside Analogues to Non-Nucleoside Analogues.
Csir-Indian Institute of Chemical Biology
Protein Lysine Methyltransferase SMYD2: A Promising Small Molecule Target for Cancer Therapy.
Zhejiang University
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
China Pharmaceutical University
Discovery of Isoxazole Amides as Potent and Selective SMYD3 Inhibitors.
Glaxosmithkline
Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.
Experimental Drug Development Centre
Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.
Epizyme
